Condition: Advanced/Metastatic Solid Tumors · Relapse/Refractory Lymphoma · Sponsor: EpimAb Biotherapeutics (Suzhou)Co., Ltd.
For solid tumors and lymphoma, respectively: This study is to evaluate the safety and tolerability of EMB-07 and to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D). Pharmacokinetics (PK), immunogenicity, and the anti-multiple myeloma activity of EMB-07 will also be assessed.
This description comes directly from the study's public registry record.
Sai Lou · +8613758235260 · slou@epimab.com
Junqiang He · +8618302157016 · jqhe@epimab.com
Always discuss trial participation with your own doctor first.
| Peninsula and South Eastern Haematology and Oncology Group | Frankston, Victoria, Australia | Recruiting |
| One Clinical Research | Nedlands, Western Australia, Australia | Recruiting |
| Hunan Cancer Hospital | Changsha, Hunan, China | Recruiting |
| Affiliated Hospital of Hebei University | Baoding, China | Recruiting |
| Cancer Hospital Chinese Academy of Medical Sciences | Beijing, China | Recruiting |
| The First Affiliated Hospital of Bengbu Medical College | Bengbu, China | Recruiting |
| Zhujiang Hospital of Southern Medical University | Guangzhou, China | Recruiting |
| The Affiliated Tumour Hospital of Harbin Medical University | Harbin, China | Recruiting |
| Shandong Cancer Hospital | Shandong, China | Recruiting |
| Tianjin Medical University Cancer Institue & Hospital | Tianjin, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05607498